systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-710Research ArticleСТАТЬИARTICLESФармакотерапия артериальной гипертензии в менопаузе. Взаимосвязи артериальной гипертензии и дисфункции эндотелия у женщин в менопаузе, возможности их коррекцииДорофееваГ. Б.noemail@neicon.ruДорофеевВ. И.noemail@neicon.ruТрофимоваЮ. В.noemail@neicon.ruДжиоеваЕ. К.noemail@neicon.ruМанероваО. В.noemail@neicon.ruСанкт-Петербургская медицинская академия последипломного образования Минздравсоцразвития РФRussian Federation20110902202384510Copyright © Дорофеева Г.Б., Дорофеев В.И., Трофимова Ю.В., Джиоева Е.К., Манерова О.В., 20232023Дорофеева Г.Б., Дорофеев В.И., Трофимова Ю.В., Джиоева Е.К., Манерова О.В.Дорофеева Г.Б., Дорофеев В.И., Трофимова Ю.В., Джиоева Е.К., Манерова О.В.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/710ReferencesАгеев Ф.Т. Диастолическая дисфункция как проявление ремоделирования сердца. Агеев Ф.Т., Овчинников А.Г. Сердечная недостаточность. 2002; 3: 190-5.Агеев Ф.Т. Диастолическая дисфункция как проявление ремоделирования сердца. Агеев Ф.Т., Овчинников А.Г. Сердечная недостаточность. 2002; 3: 190-5.Арутюнов Г.П. Клинические исследования, завершившиеся в 2002 году, в свете кардиологического континуума. Арутюнов Г.П., Розанов А.В. Клиническая фармакология и терапия. 2003; 3: 20-4.Арутюнов Г.П. Клинические исследования, завершившиеся в 2002 году, в свете кардиологического континуума. Арутюнов Г.П., Розанов А.В. Клиническая фармакология и терапия. 2003; 3: 20-4.Беленков Ю.Н. Сердечно-сосудистый континуум. Беленков Ю.Н., Мареев В.Ю. Сердечная недостаточность. 2002; 3: 7-11.Беленков Ю.Н. Сердечно-сосудистый континуум. Беленков Ю.Н., Мареев В.Ю. Сердечная недостаточность. 2002; 3: 7-11.Подзолков В.И. Ренин-ангиотензин-альдостероновая система как краеугольный камень сердечно-сосудистого и почечного континуума. Органопротективные свойства антагонистов рецепторов к ангиотензину II. Подзолков В.И., Булатов В.А. Кардиология. 2005; 3: 20-5.Подзолков В.И. Ренин-ангиотензин-альдостероновая система как краеугольный камень сердечно-сосудистого и почечного континуума. Органопротективные свойства антагонистов рецепторов к ангиотензину II. Подзолков В.И., Булатов В.А. Кардиология. 2005; 3: 20-5.Хурс Е.М. Закономерности ремоделирования сердца при артериальной гипертензии на этапах сердечно-сосудистого континуума и возможности его медикаментозной коррекции: автореф. дис. ... док. мед. наук. Екатеринбург; 2010. с. 54.Хурс Е.М. Закономерности ремоделирования сердца при артериальной гипертензии на этапах сердечно-сосудистого континуума и возможности его медикаментозной коррекции: автореф. дис. ... док. мед. наук. Екатеринбург; 2010. с. 54.Кардиоваскулярная терапия и профилактика. Национальные рекомендации. 2011; 6: 64.Кардиоваскулярная терапия и профилактика. Национальные рекомендации. 2011; 6: 64.Mendelsohn M, Karas R. The protective effects of estrogen on cardiovascular system. N Engl J Med 1999; 34: 1801-11.Mendelsohn M, Karas R. The protective effects of estrogen on cardiovascular system. N Engl J Med 1999; 34: 1801-11.Bolego C, Cignarella A, Sanvito P et al. The acute estrogenic dilation of rat aorta is mediated solely by selective estrogen receptor-a agonists and is abolished by estrogen deprivation. J Pharm and Exp Ther 2005; 313: 1203-8.Bolego C, Cignarella A, Sanvito P et al. The acute estrogenic dilation of rat aorta is mediated solely by selective estrogen receptor-a agonists and is abolished by estrogen deprivation. J Pharm and Exp Ther 2005; 313: 1203-8.Hodgin JB, Knowles JW, Kim HS et al. Interactions between endothelial nitric oxide synthase and sex hormones in vascular protection in mice. J Clin Invest 2002; 109 (4): 541-8.Hodgin JB, Knowles JW, Kim HS et al. Interactions between endothelial nitric oxide synthase and sex hormones in vascular protection in mice. J Clin Invest 2002; 109 (4): 541-8.Saitta A, Altavilla D, Cucinotta D et al. Randomized, double-blind, placebo-controlled Study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001; 21: 1512-8.Saitta A, Altavilla D, Cucinotta D et al. Randomized, double-blind, placebo-controlled Study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001; 21: 1512-8.Cox MW, Fu W, Chai H et al. Effects of progesterone and estrogen on endothelial dysfunction in porcine coronary arteries. J Surg Res 2005; 124 (1): 104-11.Cox MW, Fu W, Chai H et al. Effects of progesterone and estrogen on endothelial dysfunction in porcine coronary arteries. J Surg Res 2005; 124 (1): 104-11.Santos RL, Abreu GR, Bissoli NS et al. Endothelial mediators of 17b-estradiol-induced coronary vasodilation in the isolated rat heart. Braz J Med Biol Res 2004; 37 (4): 569-75.Santos RL, Abreu GR, Bissoli NS et al. Endothelial mediators of 17b-estradiol-induced coronary vasodilation in the isolated rat heart. Braz J Med Biol Res 2004; 37 (4): 569-75.Tostes RC, Nigro D, Fortes ZB et al. Effects of estrogen on the vascular system. Braz J Med Biol Res 2003; 36 (9): 1143-58.Tostes RC, Nigro D, Fortes ZB et al. Effects of estrogen on the vascular system. Braz J Med Biol Res 2003; 36 (9): 1143-58.Mikkola T, Viinikka L, Ylkorkala O. Administration of transdermal estrogen without progestin increases the capacity of plasma and serum to stimulate prostacyclin production in human vascular endothelial cells. Fertil Steril 2000; 73: 72-4.Mikkola T, Viinikka L, Ylkorkala O. Administration of transdermal estrogen without progestin increases the capacity of plasma and serum to stimulate prostacyclin production in human vascular endothelial cells. Fertil Steril 2000; 73: 72-4.Moyses MR, Barker LA, Cabral AM. Sex hormone modulation of serotonin-induced coronary vasodilation in isolated heart. Braz J Med Biol Res 2001; 34 (7): 949-58.Moyses MR, Barker LA, Cabral AM. Sex hormone modulation of serotonin-induced coronary vasodilation in isolated heart. Braz J Med Biol Res 2001; 34 (7): 949-58.Ma L, Yu Z, Xiao S et al. Supersensitivity to serotonin- and histamine-induced arterial contraction following ovariectomy. Eur J Pharmacol 1998; 359 (2): 191-200.Ma L, Yu Z, Xiao S et al. Supersensitivity to serotonin- and histamine-induced arterial contraction following ovariectomy. Eur J Pharmacol 1998; 359 (2): 191-200.David FL, Carvalho MH, Cobra AL et al. Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats. Hypertension 2001; 38 (2): 692-6.David FL, Carvalho MH, Cobra AL et al. Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats. Hypertension 2001; 38 (2): 692-6.Polderman KH, Stehouwer CD, van Kamp GJ et al. Modulation of plasma endothelin levels by the menstrual cycle. Metabolism 2000; 49 (5): 648-50.Polderman KH, Stehouwer CD, van Kamp GJ et al. Modulation of plasma endothelin levels by the menstrual cycle. Metabolism 2000; 49 (5): 648-50.Patterson E, Ma L, Szabo B et al. Ovariectomy and estrogen-induced alterations in myocardial contractility in female rabbits: role of the L-type calcium channel. Pharm Еxp Тher 1998; 284 (2): 586-91.Patterson E, Ma L, Szabo B et al. Ovariectomy and estrogen-induced alterations in myocardial contractility in female rabbits: role of the L-type calcium channel. Pharm Еxp Тher 1998; 284 (2): 586-91.Bednarek-Tupikowska G. Antioxidant properties of estrogens. Ginekol Pol 2002; 73 (1): 61-7.Bednarek-Tupikowska G. Antioxidant properties of estrogens. Ginekol Pol 2002; 73 (1): 61-7.Ruiz-Larrea MB, Martin C, Martinez R et al. Antioxidant activities of estrogens against aqueous and lipophilic radicals; differences between phenol and catechol estrogens. Chem Phys Lipids 2000; 105 (2): 179-88.Ruiz-Larrea MB, Martin C, Martinez R et al. Antioxidant activities of estrogens against aqueous and lipophilic radicals; differences between phenol and catechol estrogens. Chem Phys Lipids 2000; 105 (2): 179-88.Reyes MR, Sifuentes-Alvarez A, Lazalde B. Estrogens are potentially the only steroids with an antioxidant role in pregnancy: in vitro evidence. Acta Obstet Gynecol Scand 2006; 85 (9): 1090-3.Reyes MR, Sifuentes-Alvarez A, Lazalde B. Estrogens are potentially the only steroids with an antioxidant role in pregnancy: in vitro evidence. Acta Obstet Gynecol Scand 2006; 85 (9): 1090-3.Krstevska M, Dzhekova-Stojkova S, Bosilkova G. Menopause, coronary artery disease and antioxidants. Clin Chem Lab Med 2001; 39 (7): 641-4.Krstevska M, Dzhekova-Stojkova S, Bosilkova G. Menopause, coronary artery disease and antioxidants. Clin Chem Lab Med 2001; 39 (7): 641-4.Wassmann K, Wassmann S, Nickenig G. Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function. Circ Res 2005; 97 (10): 1046-54.Wassmann K, Wassmann S, Nickenig G. Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function. Circ Res 2005; 97 (10): 1046-54.Delibasi T, Kockar C, Celik A et al. Antioxidant effects of hormone replacement therapy in postmenopausal women. Swiss Med Wkly 2006; 136 (31): 510-4.Delibasi T, Kockar C, Celik A et al. Antioxidant effects of hormone replacement therapy in postmenopausal women. Swiss Med Wkly 2006; 136 (31): 510-4.Shelley JM, Green A, Smith AM et al. Relationship of endogenous sex hormones to lipids and blood pressure in mid-aged women. Ann Epidemiol 1998; 8: 39-45.Shelley JM, Green A, Smith AM et al. Relationship of endogenous sex hormones to lipids and blood pressure in mid-aged women. Ann Epidemiol 1998; 8: 39-45.Ceconi C, Francolini G, Bastianon D et al. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis in vivo and in vivo studies. Cardovasc Drugs Ther 2007; 21: 423-9.Ceconi C, Francolini G, Bastianon D et al. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis in vivo and in vivo studies. Cardovasc Drugs Ther 2007; 21: 423-9.Bots ML, Remme WJ, Luscher TF et al. ACE Inhibition and Endothelial Function: Main Findings of PERFECT, a Sub-Study of the EUROPA Trial Cardiovasc Drugs Ther 2007; 21 (4): 269-79.Bots ML, Remme WJ, Luscher TF et al. ACE Inhibition and Endothelial Function: Main Findings of PERFECT, a Sub-Study of the EUROPA Trial Cardiovasc Drugs Ther 2007; 21 (4): 269-79.Bots ML, Remme WJ, Luscher TF et al. ACE Inhibition and Endothelial Function: Main Findings of PERFECT, a Sub-Study of the EUROPA Trial Cardiovasc Drugs Ther 2007; 21 (4): 269-79.Bots ML, Remme WJ, Luscher TF et al. ACE Inhibition and Endothelial Function: Main Findings of PERFECT, a Sub-Study of the EUROPA Trial Cardiovasc Drugs Ther 2007; 21 (4): 269-79.Vrabik M, Freiberger T, Lanska V. The ATRACTIV Project: Improved Cardiovascular Prevention in the Context of Primary Care in the Czech Republic. Vnitr Lek 2008; 54 (12): 871-8.Vrabik M, Freiberger T, Lanska V. The ATRACTIV Project: Improved Cardiovascular Prevention in the Context of Primary Care in the Czech Republic. Vnitr Lek 2008; 54 (12): 871-8.Perkovic V, Ninomiya T, Arima H et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol 2007; 18 (10): 2766-72.Perkovic V, Ninomiya T, Arima H et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol 2007; 18 (10): 2766-72.
The authors declare that there are no conflicts of interest present.